{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T19:10:08Z","timestamp":1750619408498,"version":"3.41.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,22]]},"DOI":"10.7759\/cureus.86546","type":"journal-article","created":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T18:32:06Z","timestamp":1750617126000},"source":"Crossref","is-referenced-by-count":0,"title":["Angiotensin II in Catecholamine-Refractory Shock: A Systematic Review and Exploratory Analysis of the Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) Trial"],"prefix":"10.7759","author":[{"given":"S.","family":"Khallikane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youssef","family":"Qamouss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monsef","family":"Elabdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelmajid","family":"Bouzerda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Khatouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Zyani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachid","family":"Seddiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201911-2172OC","article-title":"Renin and survival in patients given angiotensin ii for catecholamine-resistant vasodilatory shock. A clinical trial","volume":"202","author":"Bellomo R","year":"2020","unstructured":"Bellomo R, Forni LG, Busse LW, et al.. Renin and survival in patients given angiotensin ii for catecholamine-resistant vasodilatory shock. A clinical trial. Am J Respir Crit Care Med. 2020, 202:1253-61. 10.1164\/rccm.201911-2172OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2022.2110067","article-title":"The pharmacotherapeutic options in patients with catecholamine-resistant vasodilatory shock","volume":"15","author":"Albertson TE","year":"2022","unstructured":"Albertson TE, Chenoweth JA, Lewis JC, Pugashetti JV, Sandrock CE, Morrissey BM. The pharmacotherapeutic options in patients with catecholamine-resistant vasodilatory shock. Expert Rev Clin Pharmacol. 2022, 15:959-76. 10.1080\/17512433.2022.2110067","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/CCE.0000000000000623","article-title":"Effectiveness of angiotensin II for catecholamine refractory septic or distributive shock on mortality: a propensity score weighted analysis of real-world experience in the medical ICU","volume":"4","author":"Quan M","year":"2022","unstructured":"Quan M, Cho N, Bushell T, et al.. Effectiveness of angiotensin II for catecholamine refractory septic or distributive shock on mortality: a propensity score weighted analysis of real-world experience in the medical ICU. Crit Care Explor. 2022, 4:e0623. 10.1097\/CCE.0000000000000623","journal-title":"Crit Care Explor"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704154","article-title":"Angiotensin II for the treatment of vasodilatory shock","volume":"377","author":"Khanna A","year":"2017","unstructured":"Khanna A, English SW, Wang XS, et al.. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017, 377:419-30. 10.1056\/NEJMoa1704154","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/burnst\/tkae081","article-title":"Haemodynamic management of septic shock","volume":"13","author":"Kotani Y","year":"2025","unstructured":"Kotani Y, Ryan N, Udy AA, Fujii T. Haemodynamic management of septic shock. Burns Trauma. 2025, 13:tkae081. 10.1093\/burnst\/tkae081","journal-title":"Burns Trauma"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.029787","article-title":"State of shock: contemporary vasopressor and inotrope use in cardiogenic shock","volume":"12","author":"Bloom JE","year":"2023","unstructured":"Bloom JE, Chan W, Kaye DM, Stub D. State of shock: contemporary vasopressor and inotrope use in cardiogenic shock. J Am Heart Assoc. 2023, 12:e029787. 10.1161\/JAHA.123.029787","journal-title":"J Am Heart Assoc"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13010016","article-title":"A new perspective on the renin-angiotensin system","volume":"13","author":"Martyniak A","year":"2022","unstructured":"Martyniak A, Tomasik PJ. A new perspective on the renin-angiotensin system. Diagnostics (Basel). 2022, 13:16. 10.3390\/diagnostics13010016","journal-title":"Diagnostics (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105916","article-title":"Dysregulation of the renin-angiotensin system in septic shock: Mechanistic insights and application of angiotensin II in clinical management","volume":"174","author":"Senatore F","year":"2021","unstructured":"Senatore F, Balakumar P, Jagadeesh G. Dysregulation of the renin-angiotensin system in septic shock: Mechanistic insights and application of angiotensin II in clinical management. Pharmacol Res. 2021, 174:105916. 10.1016\/j.phrs.2021.105916","journal-title":"Pharmacol Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2021.07.021","article-title":"Angiotensin II: a review of current literature","volume":"36","author":"Alam A","year":"2022","unstructured":"Alam A, Sovic W, Gill J, et al.. Angiotensin II: a review of current literature. J Cardiothorac Vasc Anesth. 2022, 36:1180-7. 10.1053\/j.jvca.2021.07.021","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/OAEM.S391167","article-title":"How effective is angiotensin II in decreasing mortality of vasodilatory shock? A systematic review","volume":"15","author":"Semedi BP","year":"2023","unstructured":"Semedi BP, Rehatta NM, Soetjipto S, Nugraha J, Mahyuddin MH, Arnindita JN, Wairooy NA. How effective is angiotensin II in decreasing mortality of vasodilatory shock? A systematic review. Open Access Emerg Med. 2023, 15:1-11. 10.2147\/OAEM.S391167","journal-title":"Open Access Emerg Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000003092","article-title":"Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II","volume":"46","author":"Tumlin JA","year":"2018","unstructured":"Tumlin JA, Murugan R, Deane AM, et al.. Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II. Crit Care Med. 2018, 46:949-57. 10.1097\/CCM.0000000000003092","journal-title":"Crit Care Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-024-07995-0","article-title":"The scientific rationale and study protocol for the DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) randomized controlled trial: serum biomarkers to predict response to angiotensin II versus standard-of-care vasopressor therapy in the treatment of septic shock","volume":"25","author":"Teixeira JP","year":"2024","unstructured":"Teixeira JP, Perez Ingles D, Barton JB, et al.. The scientific rationale and study protocol for the DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) randomized controlled trial: serum biomarkers to predict response to angiotensin II versus standard-of-care vasopressor therapy in the treatment of septic shock. Trials. 2024, 25:182. 10.1186\/s13063-024-07995-0","journal-title":"Trials"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-023-04446-1","article-title":"Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial","volume":"27","author":"Wieruszewski PM","year":"2023","unstructured":"Wieruszewski PM, Bellomo R, Busse LW, et al.. Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial. Crit Care. 2023, 27:175. 10.1186\/s13054-023-04446-1","journal-title":"Crit Care"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2021.170733","article-title":"The renin-angiotensin system and cardiovascular autonomic control in aging","volume":"150","author":"Miller AJ","year":"2022","unstructured":"Miller AJ, Arnold AC. The renin-angiotensin system and cardiovascular autonomic control in aging. Peptides. 2022, 150:170733. 10.1016\/j.peptides.2021.170733","journal-title":"Peptides"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2022.10.006","article-title":"Adrenal aging and its effects on the stress response and immunosenescence","volume":"168","author":"Stamou MI","year":"2023","unstructured":"Stamou MI, Colling C, Dichtel LE. Adrenal aging and its effects on the stress response and immunosenescence. Maturitas. 2023, 168:13-9. 10.1016\/j.maturitas.2022.10.006","journal-title":"Maturitas"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7110400","article-title":"Shared features of endothelial dysfunction between sepsis and its preceding risk factors (aging and chronic disease)","volume":"7","author":"Bermejo-Martin JF","year":"2018","unstructured":"Bermejo-Martin JF, Mart\u00edn-Fernandez M, L\u00f3pez-Mestanza C, Duque P, Almansa R. Shared features of endothelial dysfunction between sepsis and its preceding risk factors (aging and chronic disease). J Clin Med. 2018, 7:400. 10.3390\/jcm7110400","journal-title":"J Clin Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-022-00885-4","article-title":"The role of angiotensin II in poisoning-induced shock-a review","volume":"18","author":"Chen A","year":"2022","unstructured":"Chen A, Wong A. The role of angiotensin II in poisoning-induced shock-a review. J Med Toxicol. 2022, 18:145-54. 10.1007\/s13181-022-00885-4","journal-title":"J Med Toxicol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00038.2017","article-title":"Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology","volume":"98","author":"Forrester SJ","year":"2018","unstructured":"Forrester SJ, Booz GW, Sigmund CD, et al.. Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology. Physiol Rev. 2018, 98:1627-738. 10.1152\/physrev.00038.2017","journal-title":"Physiol Rev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-024-04910-6","article-title":"ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock","volume":"28","author":"Leisman DE","year":"2024","unstructured":"Leisman DE, Handisides DR, Busse LW, et al.. ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock. Crit Care. 2024, 28:130. 10.1186\/s13054-024-04910-6","journal-title":"Crit Care"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s44158-024-00150-w","article-title":"Angiotensin ii therapy in refractory septic shock: which patient can benefit most? A narrative review","volume":"4","author":"Coloretti I","year":"2024","unstructured":"Coloretti I, Genovese A, Teixeira JP, et al.. Angiotensin ii therapy in refractory septic shock: which patient can benefit most? A narrative review. J Anesth Analg Crit Care. 2024, 4:13. 10.1186\/s44158-024-00150-w","journal-title":"J Anesth Analg Crit Care"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.08.016","article-title":"Terlipressin and the treatment of hepatorenal syndrome: how the CONFIRM trial moves the story forward","volume":"79","author":"Belcher JM","year":"2022","unstructured":"Belcher JM, Parada XV, Simonetto DA, et al.. Terlipressin and the treatment of hepatorenal syndrome: how the CONFIRM trial moves the story forward. Am J Kidney Dis. 2022, 79:737-45. 10.1053\/j.ajkd.2021.08.016","journal-title":"Am J Kidney Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.174615","article-title":"Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment","volume":"59","author":"Wong F","year":"2010","unstructured":"Wong F, Raina N, Richardson R. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment. Gut. 2010, 59:381-6. 10.1136\/gut.2008.174615","journal-title":"Gut"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000005595","article-title":"The comparative effectiveness of vasoactive treatments for hepatorenal syndrome: a systematic review and network meta-analysis","volume":"50","author":"Pitre T","year":"2022","unstructured":"Pitre T, Kiflen M, Helmeczi W, et al.. The comparative effectiveness of vasoactive treatments for hepatorenal syndrome: a systematic review and network meta-analysis. Crit Care Med. 2022, 50:1419-29. 10.1097\/CCM.0000000000005595","journal-title":"Crit Care Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(00)03495-4","article-title":"Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group","volume":"356","author":"Bellomo R","year":"2000","unstructured":"Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet. 2000, 356:2139-43. 10.1016\/s0140-6736(00)03495-4","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022070","article-title":"Myogenic vasoconstriction requires canonical G(q\/11) signaling of the angiotensin II type 1 receptor","volume":"11","author":"Cui Y","year":"2022","unstructured":"Cui Y, Kassmann M, Nickel S, et al.. Myogenic vasoconstriction requires canonical G(q\/11) signaling of the angiotensin II type 1 receptor. J Am Heart Assoc. 2022, 11:e022070. 10.1161\/JAHA.121.022070","journal-title":"J Am Heart Assoc"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.121.17824","article-title":"Macrophage 12(S)-HETE enhances angiotensin II-induced contraction by a BLT2 (leukotriene B(4) type-2 receptor) and TP (thromboxane receptor)-mediated mechanism in murine arteries","volume":"79","author":"Kriska T","year":"2022","unstructured":"Kriska T, Herrnreiter A, Pfister SL, Adebesin A, Falck JR, Campbell WB. Macrophage 12(S)-HETE enhances angiotensin II-induced contraction by a BLT2 (leukotriene B(4) type-2 receptor) and TP (thromboxane receptor)-mediated mechanism in murine arteries. Hypertension. 2022, 79:104-14. 10.1161\/HYPERTENSIONAHA.121.17824","journal-title":"Hypertension"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2024.06.1248","article-title":"Angiotensin II: a salvage therapy in catecholamine-resistant vasodilatory shock due to calcium channel blockers and ACE inhibitors overdose","volume":"166","author":"Younas Z","year":"2024","unstructured":"Younas Z, Upadhyay R, Chaudhary M. Angiotensin II: a salvage therapy in catecholamine-resistant vasodilatory shock due to calcium channel blockers and ACE inhibitors overdose. Chest. 2024, 166:2010-1. 10.1016\/j.chest.2024.06.1248","journal-title":"Chest"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.06.127","article-title":"Vasopressor hormones in shock-noradrenaline, vasopressin or angiotensin II: which one will make the race?","volume":"9","author":"D\u00fcnser MW","year":"2017","unstructured":"D\u00fcnser MW, Meier J. Vasopressor hormones in shock-noradrenaline, vasopressin or angiotensin II: which one will make the race?. J Thorac Dis. 2017, 9:1843-7. 10.21037\/jtd.2017.06.127","journal-title":"J Thorac Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000000935","article-title":"Practice Guidelines for Obstetric Anesthesia: An Updated Report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia and the Society for Obstetric Anesthesia and Perinatology","volume":"124","year":"2016","unstructured":"Practice Guidelines for Obstetric Anesthesia. An Updated Report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia and the Society for Obstetric Anesthesia and Perinatology. Anesthesiology. 2016, 124:270-300. 10.1097\/ALN.0000000000000935","journal-title":"Anesthesiology"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2017.02.016","article-title":"Multidisciplinary team learning in the management of the morbidly adherent placenta: outcome improvements over\u00a0time","volume":"216","author":"Shamshirsaz AA","year":"2017","unstructured":"Shamshirsaz AA, Fox KA, Erfani H, et al.. Multidisciplinary team learning in the management of the morbidly adherent placenta: outcome improvements over\u00a0time. Am J Obstet Gynecol. 2017, 216:612.e1-5. 10.1016\/j.ajog.2017.02.016","journal-title":"Am J Obstet Gynecol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/379513-angiotensin-ii-in-catecholamine-refractory-shock-a-systematic-review-and-exploratory-analysis-of-the-angiotensin-ii-for-the-treatment-of-high-output-shock-athos-3-trial","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T18:32:06Z","timestamp":1750617126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/379513-angiotensin-ii-in-catecholamine-refractory-shock-a-systematic-review-and-exploratory-analysis-of-the-angiotensin-ii-for-the-treatment-of-high-output-shock-athos-3-trial"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,22]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.86546","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,22]]}}}